Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 62.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,929 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,083 shares during the period. MidWestOne Financial Group Inc.’s holdings in Jazz Pharmaceuticals were worth $2,234,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of JAZZ. Kovack Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 88.8% during the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after buying an additional 26,628 shares in the last quarter. John G Ullman & Associates Inc. purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $3,631,000. Swedbank AB acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $106,936,000. Vanguard Group Inc. boosted its stake in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. Finally, APG Asset Management US Inc. purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $1,389,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 0.7 %

Shares of JAZZ stock opened at $110.93 on Friday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The company has a market capitalization of $7.00 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 1.36 and a beta of 0.57. The stock’s 50 day simple moving average is $111.02 and its 200 day simple moving average is $110.82. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $137.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. As a group, research analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the subject of a number of research analyst reports. UBS Group reduced their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a report on Tuesday, July 2nd. Needham & Company LLC restated a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.